A Study of UCB and MSCs in Children With CP: ACCeNT-CP

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

91 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-10

Study Completion Date

2021-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to estimate change in motor function 12 months after treatment with a single dose of allogeneic umbilical cord blood (AlloCB) or repeated doses of umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in children with cerebral palsy. In addition, this study will contribute much needed data to the clinical trials community on the natural history of the motor function in CP over short-term (less than 1 year) time periods relevant to the conduct of clinical trials and assess the safety of AlloCB and hCT-MSC infusion in children with cerebral palsy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy

NCT01147653

Cerebral Palsy CP Spastic Cerebral Palsy

COMPLETED PHASE2

Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Intravenous Infusion for CP

NCT05018871

Cerebral Palsy

SUSPENDED PHASE1

Stem Cells in Umbilical Blood Infusion for CP

NCT03087110

Cerebral Palsy

COMPLETED PHASE1

Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children

NCT01072370

Cerebral Palsy

WITHDRAWN PHASE1/PHASE2

Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy

NCT03078621

Cerebral Palsy

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a phase I/II, prospective, randomized, open-label trial designed to determine the effect size of change in GMFM-66 score in subjects treated with hCT-MSC or allogeneic CB and assess the safety of repeated doses of hCT-MSC in children with cerebral palsy. Children ages 2-5 years with cerebral palsy due to hypoxic ischemic encephalopathy, stroke, or periventricular leukomalacia may be eligible to participate. All participants will ultimately be treated with an allogeneic cell product at some point during the study. Participants will be randomized to one of three arms: (1) the "AlloCB" arm will receive one allogeneic CB infusion at the baseline visit; (2) the "MSC" arm will receive three hCT-MSC infusions, one each at baseline, three months, and six months; (3) the "natural history" arm will not receive an infusion at baseline but will receive an allogeneic CB infusion at 12 months. Motor outcome measures will be assessed at baseline, six-months, and one-year time points. Safety will be evaluated at each infusion visit and remotely for an additional 12 months after the final visit. Duration of study participation will be 24 months from the time of baseline visit. Randomization to treatment arms will be stratified by GMFCS level at study entry and etiology of CP (Stroke vs. Other).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Palsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Every attempt will be made to blind the outcomes assessor.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Allogeneic Umbilical Cord Blood

Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells

Group Type EXPERIMENTAL

Infusion of allogeneic umbilical cord blood

Intervention Type BIOLOGICAL

Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.

Cord Tissue Mesenchymal Stromal Cells

Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors

Group Type EXPERIMENTAL

Infusion of MSCs

Intervention Type BIOLOGICAL

Subjects will receive 3 infusions of MSCs (baseline, 3 months and 6 months).

Natural History

Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy.

Group Type ACTIVE_COMPARATOR

Infusion of allogeneic umbilical cord blood

Intervention Type BIOLOGICAL

Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Infusion of allogeneic umbilical cord blood

Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.

Intervention Type BIOLOGICAL

Infusion of MSCs

Subjects will receive 3 infusions of MSCs (baseline, 3 months and 6 months).

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥24 months and ≤60 months adjusted age at the time of enrollment.
2. Diagnosis: Unilateral or bilateral hypertonic cerebral palsy secondary to in utero or perinatal stroke/hemorrhage, hypoxic ischemic encephalopathy (including, but not limited to, birth asphyxia), and/or periventricular leukomalacia.
3. Performance status: Gross Motor Function Classification Score levels I - IV
4. Review of brain imaging (obtained as standard of care prior to study entry) does not suggest a genetic condition or brain malformation.
5. Legal authorized representative consent.

Exclusion Criteria

1. Available qualified autologous cord blood unit.
2. Hypotonic or ataxic cerebral palsy without spasticity.
3. Autism and autistic spectrum disorders.
4. Hypsarrhythmia.
5. Legally blind
6. Intractable seizures causing epileptic encephalopathy.
7. Evidence of a progressive neurologic disease.
8. Has an active, uncontrolled systemic infection or documentation of HIV+ status.
9. Known genetic disease or phenotypic evidence of a genetic disease on physical exam.
10. Concurrent genetic or acquired disease or comorbidity(ies) that could require a future allogeneic stem cell transplant.
11. Requires ventilatory support, including home ventilator, CPAP, BiPAP, or supplemental oxygen.
12. Impaired renal or liver function as determined by serum creatinine \>1.5mg/dL and/or total bilirubin \>1.3mg/dL except in patients with known Gilbert's disease.
13. Possible immunosuppression, defined as WBC \<3,000 cells/mL or absolute lymphocyte count (ALC) \<1500 with abnormal T-cell subsets.
14. Patient's medical condition does not permit safe travel.
15. Previously received any form of cellular therapy.

Minimum Eligible Age

24 Months

Maximum Eligible Age

60 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No